SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001479290-20-000058
Filing Date
2020-05-07
Accepted
2020-05-07 17:23:18
Documents
61
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q rvncq12010-q.htm   iXBRL 10-Q 1567143
2 EXHIBIT 31.1 rvnc-q120exhibit311.htm EX-31.1 13019
3 EXHIBIT 31.2 rvnc-q120exhibit312.htm EX-31.2 12889
4 EXHIBIT 32.1 rvnc-q120exhibit321.htm EX-32.1 7669
5 EXHIBIT 32.2 rvnc-q120exhibit322.htm EX-32.2 7668
  Complete submission text file 0001479290-20-000058.txt   5889330

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rvnc-20200331.xsd EX-101.SCH 38318
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rvnc-20200331_cal.xml EX-101.CAL 67859
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rvnc-20200331_def.xml EX-101.DEF 187699
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rvnc-20200331_lab.xml EX-101.LAB 534928
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rvnc-20200331_pre.xml EX-101.PRE 312649
15 EXTRACTED XBRL INSTANCE DOCUMENT rvncq12010-q_htm.xml XML 823604
Mailing Address 7555 GATEWAY BLVD. NEWARK CA 94560
Business Address 7555 GATEWAY BLVD. NEWARK CA 94560 510-742-3400
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36297 | Film No.: 20857720
SIC: 2834 Pharmaceutical Preparations